• Guidance for Industry: Clinical Trail Endpoints for the Approval of Cancer Drugs and Biologics.
May 2007 (Section: Clinical Medical).
• Guidance for Industry: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics. April 2015 (Section: Clinical Medical).
EMA:
• Guideline on the evaluation of anticancer medicinal products in man. 13 December 2012; EMA/CHMP/205/95/Rev.4
• Appendix 1 to the Guideline on the evaluation of anticancer medicinal products in man. 
Results (cont.):
Results for the regulatory bodies analyzed can be summarized as follows:
• In general OS and PROs are defined as outcomes of choice and PFS is considered a surrogate or a complementary outcome. Although not mentioned explicitly, this refers to the criterion of perceptibility.
• The regulatory bodies are restrictive in defining the circumstances in which an improvement in PFS is considered a direct benefit to the patient.
• Considering surrogate parameters (PFS) requires an association of PFS with definite endpoints (OS and / or PROs).
• No sufficient disease-specific validation of PFS as surrogate of OS or PROs has been identified / accepted by EMA, FDA and PDMA.
• Nevertheless, EMA, FDA and PDMA accept PFS as a relevant outcome (for regulatory purposes, which may be counter to HTA-agencies' requirements) under specific circumstances.
Conclusion :
Frequently HTA-agencies and regulatory agencies represent two different worlds at as far as the inclusion of PFS is concerned. However, taking a closer look concerning the inclusion of PFS, regulatory bodies make use of what is mostly described to be evidence based medicine. They consider a broad body of evidence (i.e. outcomes), expressing differentiated views on the suitability of PFS as a regulatory endpoint to measure efficacy in specific indications. They also express differentiated views concerning the consideration of PFS as an endpoint per se depending on specific cancer settings.
Related Podium presentation:
P10: HTA Agencies' Perspective on progression-free survival (PFS) Overall survival is the gold standard in clinical studies.
EMA (Europe) FDA (USA)
• OS should be chosen as primary endpoint for confirmatory trials.
• PFS might enable a proper benefitrisk assessment, if experimental regimen is likely to be well tolerated and supported by data on HRQoL/PRO.
• OS is recommended for maintenance trials vs. placebo / best supportive care
• OS is considered the standard clinical benefit endpoint to establish efficacy in locally advanced or mNSCLC.
• PFS may be appropriate as primary endpoint for approval if the trial is designed to demonstrate a large magnitude for the treatment effect and an acceptable risk-benefit profile is demonstrated.
• For NSCLC …to consider PFS as the basis for accelerated approval, the treatment differences had to be substantial (e.g., 3 months or more).
Tab. 3: PFS Importance Relative to Overall Survival (OS)
EMA (Europe) FDA (USA) PMDA (Japan)
• For confirmatory trials, prolonged PFS / DFS are considered to be of benefit to the patient. However, favorable effects on survival are most persuasive.
• When there is a large effect on PFS, or a long expected survival after progression, and / or a clearly favorable safety profile, precise estimates of OS may not be needed for approval.
• Choice of endpoints linked to treatment setting as well as to expected toxicity, e.g. in long-term treatment and expected toxicity of new therapy is comparable or lessened, PFS is considered appropriate.
• Consideration of improvement in PFS as a direct clinical benefit or a surrogate depends on the magnitude of the effect and the risk-benefit compared to available therapies.
• Precise definition of tumor progression is important.
• For serious / lifethreatening diseases, accelerated approval is possible on the basis of surrogates when an association with the endpoint has been sufficiently validated, specific to the indication. However, even then PFS is still considered a surrogate parameter.
• PMDA requires OS to be used as an endpoint for clinical studies. Surrogate endpoints may be used in phase 1, phase 2 and phase 2.5 studies.
• A potential factor of approval based on PFS may be orphan drug status or an accelerated approval by the FDA.
According to PDMA a randomized controlled phase 2.5 design is one of the phase 2 study protocol design. Conventional randomized phase 2 trials are to select a treatment to be applied in confirmatory trials. Trial of phase 2.5, however are performed to make comparison with a control group. Phase 2.5 trials are not confirmatory trials, enabling to apply endpoints based on anti-tumor effect and a significance level larger than 5%.
Results:
Based on the identified documents a hierarchy of endpoints in solid tumors (Table 2 ) and the importance of PFS relative to OS (Table 3) could be described.
Disease specific statements on Non-Small Cell Lung Cancer (NSCLC) were identified for FDA and EMA (Table 4) 
